Medical therapies for non-melanoma skin cancer

Clinics in Dermatology

Volumn 22, Issue 3, 2004, Pages 183-188

  Chakrabarty, Arun ^a   Geisse, John K ^b  

^a Solano Dermatology Associates   (United States)

^b UCSF Department of Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; ALPHA INTERFERON; ALPHA TOCOPHEROL; ASCORBIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; GAMMA INTERFERON; IMIQUIMOD; ISOTRETINOIN; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROCYANIDIN DERIVATIVE; RETINOID DERIVATIVE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DNA SYNTHESIS; ELECTROCHEMOTHERAPY; HUMAN; IMMUNE RESPONSE; KERATINOCYTE; LIFESTYLE; LOW FAT DIET; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SKIN CANCER;

EID: 3242683363     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.12.005     Document Type: Article

References (63)

1. Humphreys T.R. Skin cancer recognition and management. Clin Cornerstone. 4:2001;23-32
2. Nyugen T.H., Ho D.Q. Nonmelanoma skin cancer. Curr Treat Options Oncol. 3:2002;193-203
3. Housman T.S., Feldman S.R., Williford P.M., et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 48:2003;425-429
4. Bagheri M., Safai B. Cutaneous malignancies of keratinocytic origin. Clin Dermatol. 19:2001;244-252
5. Hannan E.L., Racz M.J., Walford G., et al. Predictors of readmission for complications of coronary artery bypass graft surgery. JAMA. 290:2003;773-780
6. Matin S.F., Abreu S., Ramani A., et al. Evaluation of age and comorbidity as risk factors after laparoscopic urological surgery. J Urol. 170:2003;1115-1120
7. Gibbs P., Gonzalez R., Lee L., Walsh P. Medical management of cutaneous malignancies. Clin Dermatol. 19:2001;298-304
8. Seegenschmiedt M.H., Oberste-Beulmann S., Lang E., et al. Radiotherapy for basal cell carcinoma local control and cosmetic outcome. Strahlenther Onkol. 177:2001;240-246
9. Yaparpalvi R., Mahadevia P.S., Gorla G.R. Radiation therapy for the salvage of unresectable subungual squamous cell carcinoma. Dermatol Surg. 29:2003;294-296
10. Dillaha J., Jansen G.T., Honeycutt W.M., et al. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol. 119:1983;774-783
11. Mohs F.E., Jones D.L., Bloom R.F. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 114:1978;1021-1022
12. Glass L.F., Jaroszeski M., Gilbert R., et al. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol. 37:1997;596-599
13. Khandekar J. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy a report on two patients. Arch Dermatol. 126:1990;1660
14. Baxter D. Jr, Loyce A., Feldman B., Lynch J. Jr. Cisplatin chemotherapy for basal cell carcinoma the need for posttreatment biopsy: report of a case. J Am Acad Dermatol. 23:1990;1167-1168
15. Stanley M.A. Imiquimod and the imidazoquinolones mechanism of action and therapeutic potential. Clin Exp Dermatol. 27:2002;571-577
16. Cryns V., Yuan J. Proteases to die for. Genes Dev. 12:1998;1551-1570
17. Schon M., Bong A.B., Drewniok C., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 95:2003;1138-1149
18. Slade H.B., Owens M.L., Tomai M.A., et al. Imiquimod 5% cream (Aldara). Exp Opin Invest Drugs. 7:1998;437-450
19. Cornell R.C., Greenway H.T., Tucker S.B., et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 23:1990;694-700
20. Kowalzick L., Rogozinski T., Wimheur R., et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma results of an open-label multicenter study. Eur J Dermatol. 12:2002;558-561
21. Beutner K.R., Geisse J.K., Helman D., et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 41:1999;1002-1007
22. Marks R., Gebauer K., Shumack S., et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma results of a multicenter 6-week dose response trial. J Am Acad Dermatol. 44:2001;807-813
23. Geisse J.K., Phoebe R., Pandya A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 47:2002;390-398
24. Geisse JK, Caro I, Lindholm J, et al. Efficacy and safety of imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results from 2 phase II randomized, vehicle-controlled studies. JAAD 2004;50:722-33
25. Sterry W., Ruzicka T., Herrera E., et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 147:2002;1227-1236
26. Shumack S., Robinson J., Kossard S., et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol. 138:2002;1165-1170
27. Orengo I., Rosen T., Guill C.K. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream a case report. J Am Acad Dermatol. 47:(4 suppl):2002;S225-228
28. Schroeder T.L., Sengelmann R.D. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 46:2002;545-548
29. Berman B, Spencer J, Villa A. Treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream. Poster presented at the 11th Congress of the European Academy of Dermatology and Venereology, Prague, October 2-6, 2002
30. Ahmed I., Berth-Jones J. Imiquimod a novel treatment for lentigo maligna. Br J Dermatol. 143:2000;843-845
31. Bong A.B., Bonnekoh B., Franke I., et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 205:2002;135-138
32. Dendorfer M., Oppel T., Wollenberg A. Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol. 13:2003;80-82
33. Stockfleth E., Meyer T., Benninghoff B., Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5% a report of six cases. Br J Dermatol. 144:2001;1050-1053
34. Salasche S.J., Levine N., Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream an open-label trial. J Am Acad Dermatol. 47:2002;571-577
35. Suchin K.R., Junkins-Hopkins J.M., Rook A.H. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol. 138:2002;1137-1139
36. Niles R.M. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother. 3:2002;299-303
37. Noble S., Wagstaff A.J. Tretinoin. A review of its pharmacological properties and clinical efficacy in the topical treatment of photodamaged skin. Drugs Aging. 6:1995;479-496
38. Niles R.M. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 16:2000;1084-1089
39. Peris K., Fargnoli M.C., Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med. 341:1999;1767-1768
40. De Sevaux R.G., Smit J.V., De Jong E.M., et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol. 49:2003;407-412
41. Levine N. The evolving role of retinoids in the management of cutaneous conditions. J Am Acad Dermatol. 39:1998;62-66
42. Alpsoy E., Yilmaz E., Basaran E., Yazar S. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol. 23:1996;394-396
43. Greenway H.T., Cornell R.C., Tanner J.T., et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 15:1986;437-443
44. Buechner S.A., Wernli M., Harr T., et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest. 100:1997;2691-2696
45. Kim J., Modlin R.L., Moy R.L., et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol. 155:1995;2240-2247
46. Ferenczi K., Yawalkar N., Jones D., et al. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Arch Dermatol. 139:2003;909-913
47. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188
48. Watanabe O., Shimizu T., Imamura H., et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res. 23:2003;3215-3221
49. Buckman S.Y., Gresham A., Hale P., et al. COX-2 expression is induced by UVB exposure in human skin; implications for the development of skin cancer. Carcinogenesis. 19:1998;723-729
50. Athar M., An K.P., Morel K.D., et al. Ultraviolet B (UVB)-induced COX-2 expression in murine skin an immunohistochemical study. Biochem Biophys Res Commun. 280:2001;1042-1047
51. Pentland A.P., Schoggins J.W., Scott G.A., et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 20:1999;1939-1944
52. Wilgus T.A., Koki A.T., Zweifel B.S. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog. 38:2003;33-39
53. Fuller C.J., Faulkner H., Bendich A., Parker R.S., Roe D.A. Effect of β-carotene supplementation on photosuppression of delayed type hypersensitivity in normal young men. Am J Clin Nutr. 56:1992;684-690
54. Greenberg E.R., Baron J.A., Stukel T.A., et al. A clinical trial of β-carotene to prevent basal-cell and squamous-cell cancers of the skin. N Engl J Med. 32:1990;3789-3795
55. Eberlein-Konig B., Placzek M., Przybilla B. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (Vitamin E). J Am Acad Dermatol. 38:1998;45-48
56. Fuchs J., Kern H. Modulation of UV-light-induced skin inflammation by d-alpha-tocopherol and l-ascorbic acid a clinical study using solar simulated radiation. Free Radic Biol Med. 25:1998;1006-1012
57. Dreher F., Gabard B., Schwindt D.A., Maibach H.I. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema a human study in vivo. Br J Dermatol. 139:1998;332-339
58. McVean M., Liebler D.C. Inhibition of UVB induced DNA photodamage in mouse epidermis by topically applied α-tocopherol. Carcinogenesis. 18:1997;1617-1622
59. Black H.S. Influence of dietary factors on actinically-induced skin cancer. Mutat Res. 422:1998;185-190
60. Danielsson C., Fehsel K., Polly P., Carlberg C. Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ. 5:1998;946-952
61. Bickers D.R., Athar M. Novel approaches to chemoprevention of skin cancer. J Dermatol. 27:2000;691-695
62. Katiyar S.K., Bergamo B.M., Vyalil P.K. Green tea polyphenols DNA photodamage and photoimmunology. J Photochem Photobiol B. 65:2001;109-114
63. Zhao J., Wang J., Agarwal R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis. 20:1999;1737-1745